Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Diagnostic usefulness of the Janus kinase 2 mutation in non BCR/ABL myeloproliferative disorders.

The Korean journal of internal medicine - 1 Dec 2006

Bang Soo-Mee, Ahn Jeong Yeal, Park Jiyoon, Yoo Soo Jin, Park Se Hoon, Nam Eun Mi, Park Pil Whan, Seo Yiel Hea, Cho Eun Kyung, Shin Dong Bok, Lee Jae Hoon

Abstract excerpt

BACKGROUND: We investigated the Janus kinase 2 (JAK2) mutation and its diagnostic value in patients suffering with non BCR/ABL myeloproliferative diseases (nMPD) or other reactive conditions. METHODS: We reviewed the clinical records of 83 patients who underwent bone marrow (BM) examinations with suspect of nMPD. The diagnoses of nMPD were made based on the WHO criteria since 2001 and the PVSG criteria before...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diagnosis, Differential

Share to Genes, abl

Share to Janus Kinase 2

Share to Myeloproliferative Disorders

Share to Polymerase Chain Reaction

Source

Open in PubMed Open full text

Identifiers

PMID: 17249502
DOI: 10.3904/kjim.2006.21.4.219
PMCID: PMC3891025

Genes

JAK2
BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diagnostic usefulness of the Janus kinase 2 mutation in non BCR/ABL myeloproliferative disorders.PMID 17249502Read ↗

Clinical implications of JAK2 mutations in myeloproliferative disorders.Semantic proximity Read ↗

The spectrum of JAK2-positive myeloproliferative neoplasmsSemantic proximity Read ↗

Clinical applications of molecular haematology: JAK2 in myeloproliferative disorders.Semantic proximity Read ↗

Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.Semantic proximity Read ↗

Validation of the revised 2008 WHO diagnostic criteria in 75 suspected cases of myeloproliferative neoplasm.Semantic proximity Read ↗

Janus kinase mutations.Semantic proximity Read ↗

The spectrum of JAK2-positive myeloproliferative neoplasms.Semantic proximity Read ↗

JAK2 mutations and clinical practice in myeloproliferative neoplasms.Semantic proximity Read ↗

Myeloproliferative neoplasms and JAK2 mutations.Semantic proximity Read ↗

[Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection].Semantic proximity Read ↗

The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis.Semantic proximity Read ↗

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.